CA2373150A1 - Procede de diagnostic de la maladie d'alzheimer - Google Patents

Procede de diagnostic de la maladie d'alzheimer Download PDF

Info

Publication number
CA2373150A1
CA2373150A1 CA002373150A CA2373150A CA2373150A1 CA 2373150 A1 CA2373150 A1 CA 2373150A1 CA 002373150 A CA002373150 A CA 002373150A CA 2373150 A CA2373150 A CA 2373150A CA 2373150 A1 CA2373150 A1 CA 2373150A1
Authority
CA
Canada
Prior art keywords
beta
subject
peptide
disease
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373150A
Other languages
English (en)
Inventor
Allen B. Reitz
Carlos R. Plata Salaman
Adrian Dawkes
Haou-Yan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373150A1 publication Critical patent/CA2373150A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention porte sur un procédé de diagnostic de la maladie d'Alzheimer, ce procédé consistant à analyser un échantillon de plasma ou de sérum de telle façon que .beta.-amyloid¿1-42? ou A.beta.3pE soit totalement ou quasi totalement (à savoir, parfaitement) dissocié des protéines de liaison avant l'analyse des taux de .beta.-amyloid¿1-42? ou A.beta.3pE.
CA002373150A 1999-05-07 2000-05-05 Procede de diagnostic de la maladie d'alzheimer Abandoned CA2373150A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13316199P 1999-05-07 1999-05-07
US60/133,161 1999-05-07
US17997500P 2000-02-03 2000-02-03
US60/179,975 2000-02-03
PCT/US2000/012167 WO2000068694A1 (fr) 1999-05-07 2000-05-05 Procede de diagnostic de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
CA2373150A1 true CA2373150A1 (fr) 2000-11-16

Family

ID=26831109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373150A Abandoned CA2373150A1 (fr) 1999-05-07 2000-05-05 Procede de diagnostic de la maladie d'alzheimer

Country Status (4)

Country Link
EP (1) EP1177447A1 (fr)
AU (1) AU4984400A (fr)
CA (1) CA2373150A1 (fr)
WO (1) WO2000068694A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236592A1 (en) * 2000-02-03 2001-08-14 Ortho-Mcneil Pharmaceutical, Inc. Methods for diagnosis of alzheimer's disease
KR20140128229A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트

Also Published As

Publication number Publication date
WO2000068694A1 (fr) 2000-11-16
AU4984400A (en) 2000-11-21
EP1177447A1 (fr) 2002-02-06

Similar Documents

Publication Publication Date Title
US20020006627A1 (en) Method for diagnosis of Alzheimer's disease
JP5009987B2 (ja) 体液中のアミロイド−βオリゴマーの検出方法
US20080220449A1 (en) Biomarkers and assays for Alzheimer's disease
JP2004536600A (ja) 細胞に基づいた高スループットスクリーニング法
WO2015191825A1 (fr) Méthodes pour la détection et la mesure de la protéine beta amyloïde dans des échantillons biologiques
KR20140069346A (ko) 알츠하이머병 （ａｄ）을 진단하는 방법
US20070292895A1 (en) Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
Han et al. Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer's disease patients
US20150233949A1 (en) Detection and modulation of cytochrome c acetylation
Russell et al. Post-translational modifications in Alzheimer's disease and the potential for new biomarkers
WO2014011972A1 (fr) Immunodosage de tau
JP5488885B2 (ja) 感染症の疾患マーカー
JP5322556B2 (ja) 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法
Poljak et al. Quantification of hemorphins in Alzheimer's disease brains
CA2373150A1 (fr) Procede de diagnostic de la maladie d'alzheimer
Yang et al. Quantitative proteomics identifies surfactant-resistant α-synuclein in cerebral cortex of parkinsonism-dementia complex of guam but not alzheimer's disease or progressive supranuclear palsy
EP2480891B1 (fr) Interaction fkbp52-tau en tant que nouvelle cible thérapeutique pour le traitement de troubles neurologiques impliquant un dysfonctionnement tau
JP2010523977A (ja) プリオンアッセイ
WO2007140971A2 (fr) Protéines d'adhérence cellulaire utilisées en tant que biomarqueurs de la maladie d'alzheimer
WO2008031190A1 (fr) Alpha-1-antitrypsine comme indicateur de diagnostic/pronostic pour des maladies neuro-dégénératives
WO2014073885A1 (fr) Complexe de protéines étalon destiné à l'analyse quantitative de multimères de polypeptides formant des multimères
WO2019167128A1 (fr) Immunoessai en sandwich
KR20200047371A (ko) 인지기능 정상군 또는 경도 인지장애에서 아밀로이드 베타의 뇌 침착 검출용 혈액 바이오 마커
KR101363576B1 (ko) 알츠하이머 질환에 대한 신규 바이오마커 및 그의 용도
JP4217613B2 (ja) Ｐｓ２ｖの検出方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued